http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0708607-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-92 |
| filingDate | 2007-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c524fc5ee0715def6de134ac4f9d308 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e97605457769fa6b183ccfe412c1dad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_419f28913db0c4b653ec69a5c26e84df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01d467c8ab43b6003a42cf8de7b47771 |
| publicationDate | 2011-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0708607-A2 |
| titleOfInvention | 4-amino-1,5-substituted 1,5-dihydroimidazol-2-ones |
| abstract | 1,5-DIIDRO-IMIDAZOL-2-ONAS 4-AMINO-1,5-REPLACED. The present invention relates to compounds of the general formula in which R ^ 1 ^ is - (CH ~ 2) ~ n ~ -aryl or - (CH ~ 2) ~ n ~ -heteroaryl, where such groups are unsubstituted or substituted by one or more substituents, selected from the group consisting of halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkyl, cyano, nitro, -O-lower alkyl substituted by halogen or morphonyl; R ^ 2 ^ is -CH ~ 2 ~) ~ n ~ -aryl or - (CH ~ 2 ~) ~ n ~ -heteroaryl, where such groups are unsubstituted or substituted by one or more substituents, selected from the group consisting of in lower alkyl, lower alkoxy, halogen or - N (lower alkyl) ~ 2 ~; R ^ 3 ^ is hydrogen or lower alkyl; R ^ 4 ^ is -CH ~ 2 ~) ~ n ~ -aryl or - (CH ~ 2 ~) ~ n ~ -heteroaryl, where such groups are unsubstituted or substituted by one or more substituents, selected from the group consisting of in halogen or lower alkoxy, or is lower alkyl, - (CH ~ 2 ~) ~ n ~ -cycloalkyl; or R ^ 3 ^ and R ^ 4 ^ together form the heterocyclic ring with the N atom; n is 0, 1 or 2; and for pharmaceutically acceptable acid addition salts thereof. The compounds of general formula I or their tautomeric forms have been found to be good inhibitors of the glycine transporter 1 (GlyT-1), and that they have a good selectivity for glycine transporter 2 (GlyT-2) inhibitors, useful for the treatment of schizophrenia. |
| priorityDate | 2006-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 293.